Cash Flow Statement (Annual)

MBOT / Microbot Medical Inc Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss -27,026 -25,244 -21,329 -28,491 -26,439 -32,741 -36,415 -9,663 -7,589
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation - 1,093 842 728 789 1,008 1,054 10 21
    Interest Expense Debt - - - - - - - - -
    Gains Losses On Extinguishment Of Debt - - - - - - - - -2,364
    Fair Value Adjustment Of Warrants - - -6,612 5,945 -3,253 -2,422 -914 -262 -285
    Shares Issued As Consideration Vendor - - - - - - - - -
    Share Based Compensation 4,203 3,930 3,261 2,878 2,609 2,035 4,244 676 479
    Increase Decrease In Operating Capital
      Increase Decrease In Other Receivables -276 -550 79 -40 299 -193 -199 -538 14
      Increase Decrease In Other Accounts Payable And Accrued Liabilities - - - - - - 66 324 -69
  Net Cash Provided By Used In Operating Activities -24,683 -24,520 -22,058 -19,869 -23,322 -27,352 -30,679 -786 -4,856
Net Cash Provided By Used In Investing Activities
  Increase In Restricted Cash - - - - - - - - 27
  Payments To Acquire Property Plant And Equipment 701 924 297 73 4,681 904 1,054 25 58
  Net Cash Provided By Used In Investing Activities 3,732 -924 -3,422 -10,692 9,036 -426 -885 -25 -85
Net Cash Provided By Used In Financing Activities
  Outflow In Connection With Current Assets And Liabilities Acquired In Reverse Recapitalization Net - - - - - - - -2,002 -317
  Proceeds From Issuance Of Common Stock 29,603 7,279 19,775 19,748 23,492 18,950 26,325 - 12,702
  Net Cash Provided By Used In Financing Activities 29,786 6,586 19,129 25,737 36,402 22,196 18,707 3,083 13,019
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - - - - - -
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - -
Supplemental Cash Flow Elements
  Cash Flow Noncash Investing And Financing Activities Disclosure
    Cashless Exercise Of Warrants - - - - - - - - -
    Conversion Of Convertible Notes Into Preferred Shares - - - - - - - - 90

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 59503A105